November 2023 in “Journal of the American Society of Nephrology”
Transgenderindividuals can maintain stable kidney function post-transplant with gender-affirming care, but need careful management of hormone therapy risks and regular health screenings.
A transgenderindividual began MTF HRT with estradiol and spironolactone at 39 and is monitoring hair regrowth before starting minoxidil. They are hopeful about not needing wigs permanently.
A transgenderindividual is starting spironolactone and estradiol for hormone replacement therapy (HRT) and is considering adding finasteride to help with hair loss. They are also planning to use minoxidil and microneedle, but are unsure if they need to use another anti-androgen or more aggressive treatments. A respondent advises against using pyri and suggests waiting to see if the HRT alone is sufficient before becoming dependent on minoxidil.
The conversation discusses a transgenderindividual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgenderindividuals.
A 19-year-old transgenderindividual is experiencing worsening temple recession despite taking female hormones and 1.25mg finasteride. They are seeking advice on additional treatments to address hair loss.
The conversation is about a transgenderindividual's experience with hair regrowth using topical minoxidil and hormone replacement therapy (HRT), expressing concern about the slow growth and thin appearance of their hair. Some responses encourage patience and highlight the variability of results, while others discuss the role of HRT and its effects.